E.coli O157 & Haemolytic Uraemic Syndrome

HUSH supports application for feasibility study of the drug Eculizumab

5th October 2014

HUSH has supported an application for a feasibility study of the drug Eculizumab, for HUS sufferers.

The drug is currently being successfully used for sufferers of a similar illness called aHUS.

This application is supported by medical and public health experts who believe that this drug could be helpful for sufferers of HUS.

The funding application for this study to the National Institute of Health Research is at a very early stage of the process.

The application is lead by Dr Sally Johnson a Consultant Paediatric Nephrologist at Great North Children's Hospital Newcastle and is supported by Paediatric Nephrologists in England, Wales & Scotland.

If the feasibility application & study is successful it is hoped that a trial of the drug will be carried out on HUS sufferers.

1 of 47
Next > Last >>

21st June 2024

According to an update yesterday the 20th June 2024 from the  UK Health Security Agency (UKHSA) ,the number of confirmed ... on
14th June 2024

Two suppliers of Supermarket sandwiches and wraps recall products as a precaution after E.coli O145 (Shiga toxin-producing Escherichia coli often referred to as ... on
6th June 2024

The UK Health Security Agency (UKHSA) has advised of a large outbreak of Shiga toxin-producing Escherichia coli (STEC) O145, that currently appears to be spreading across the UK. This follow... on
19th April 2024

The UK Health Security Agency (UKHSA) data released yesterday 18/04/2024 for 2021 shows Shiga toxin-producing Escherichia coli (STEC) ... on
11th March 2024

According to an Article in the Guardian newspaper on Wednesday 6th March 2024 people in England are facing food poisoning ‘Russian roulette’ as... on
1 of 47
Next > Last >>

Designed by Robert Woods. View our Cookie & Privacy Policy